- Clinical score
- A numeric value derived from patient inputs that estimates risk, severity, or diagnostic likelihood for a given condition.
- Reference range
- The set of values considered normal for a healthy population, used to interpret a calculated result.
- Sensitivity
- The probability that a positive result correctly identifies a patient with the condition.
- Specificity
- The probability that a negative result correctly identifies a patient without the condition.
- Non-HDL cholesterol
- A key concept referenced by the Non-HDL Target: Calculates non-HDL cholesterol (Total Cholesterol − HDL) and compares to risk-based targets. Non-HDL goal is 30 mg/dL above the corresponding LDL-C target: <130 mg/dL (general), <100 mg/dL (high-risk), <85 mg/dL (very high-risk ASCVD). Non-HDL captures atherogenic lipoproteins including VLDL and IDL.
- Lipid target
- A key concept referenced by the Non-HDL Target: Calculates non-HDL cholesterol (Total Cholesterol − HDL) and compares to risk-based targets. Non-HDL goal is 30 mg/dL above the corresponding LDL-C target: <130 mg/dL (general), <100 mg/dL (high-risk), <85 mg/dL (very high-risk ASCVD). Non-HDL captures atherogenic lipoproteins including VLDL and IDL.
- LDL target
- A key concept referenced by the Non-HDL Target: Calculates non-HDL cholesterol (Total Cholesterol − HDL) and compares to risk-based targets. Non-HDL goal is 30 mg/dL above the corresponding LDL-C target: <130 mg/dL (general), <100 mg/dL (high-risk), <85 mg/dL (very high-risk ASCVD). Non-HDL captures atherogenic lipoproteins including VLDL and IDL.
- ASCVD risk
- A key concept referenced by the Non-HDL Target: Calculates non-HDL cholesterol (Total Cholesterol − HDL) and compares to risk-based targets. Non-HDL goal is 30 mg/dL above the corresponding LDL-C target: <130 mg/dL (general), <100 mg/dL (high-risk), <85 mg/dL (very high-risk ASCVD). Non-HDL captures atherogenic lipoproteins including VLDL and IDL.
- Dyslipidemia
- A key concept referenced by the Non-HDL Target: Calculates non-HDL cholesterol (Total Cholesterol − HDL) and compares to risk-based targets. Non-HDL goal is 30 mg/dL above the corresponding LDL-C target: <130 mg/dL (general), <100 mg/dL (high-risk), <85 mg/dL (very high-risk ASCVD). Non-HDL captures atherogenic lipoproteins including VLDL and IDL.
- Total cholesterol
- A key concept referenced by the Non-HDL Target: Calculates non-HDL cholesterol (Total Cholesterol − HDL) and compares to risk-based targets. Non-HDL goal is 30 mg/dL above the corresponding LDL-C target: <130 mg/dL (general), <100 mg/dL (high-risk), <85 mg/dL (very high-risk ASCVD). Non-HDL captures atherogenic lipoproteins including VLDL and IDL.
- HDL
- A key concept referenced by the Non-HDL Target: Calculates non-HDL cholesterol (Total Cholesterol − HDL) and compares to risk-based targets. Non-HDL goal is 30 mg/dL above the corresponding LDL-C target: <130 mg/dL (general), <100 mg/dL (high-risk), <85 mg/dL (very high-risk ASCVD). Non-HDL captures atherogenic lipoproteins including VLDL and IDL.
- Cardiovascular prevention
- A key concept referenced by the Non-HDL Target: Calculates non-HDL cholesterol (Total Cholesterol − HDL) and compares to risk-based targets. Non-HDL goal is 30 mg/dL above the corresponding LDL-C target: <130 mg/dL (general), <100 mg/dL (high-risk), <85 mg/dL (very high-risk ASCVD). Non-HDL captures atherogenic lipoproteins including VLDL and IDL.
- Statin therapy
- A key concept referenced by the Non-HDL Target: Calculates non-HDL cholesterol (Total Cholesterol − HDL) and compares to risk-based targets. Non-HDL goal is 30 mg/dL above the corresponding LDL-C target: <130 mg/dL (general), <100 mg/dL (high-risk), <85 mg/dL (very high-risk ASCVD). Non-HDL captures atherogenic lipoproteins including VLDL and IDL.